Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Antibody therapy to limit the spread of Ebola virus.

Rager-Zisman B.

Isr Med Assoc J. 2014 Dec;16(12):743. No abstract available.

2.

Protecting public health in the age of emerging infections.

Lev O, Rager-Zisman B.

Isr Med Assoc J. 2014 Nov;16(11):677-82.

3.

Ethical and regulatory challenges posed by synthetic biology.

Rager-Zisman B.

Perspect Biol Med. 2012;55(4):590-607. doi: 10.1353/pbm.2012.0043.

PMID:
23502567
4.

Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Gershoni-Yahalom O, Landes S, Kleiman-Shoval S, Ben-Nathan D, Kam M, Lachmi BE, Khinich Y, Simanov M, Samina I, Eitan A, Cohen IR, Rager-Zisman B, Porgador A.

Immunology. 2010 Aug;130(4):527-35. doi: 10.1111/j.1365-2567.2010.03251.x. Epub 2010 Mar 16.

5.

NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells.

Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, Porgador A.

J Immunol. 2009 Aug 15;183(4):2610-21. doi: 10.4049/jimmunol.0802806. Epub 2009 Jul 27.

6.

Impaired cholesterol biosynthesis in a neuronal cell line persistently infected with measles virus.

Robinzon S, Dafa-Berger A, Dyer MD, Paeper B, Proll SC, Teal TH, Rom S, Fishman D, Rager-Zisman B, Katze MG.

J Virol. 2009 Jun;83(11):5495-504. doi: 10.1128/JVI.01880-08. Epub 2009 Mar 18.

7.

Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection.

Ben-Nathan D, Gershoni-Yahalom O, Samina I, Khinich Y, Nur I, Laub O, Gottreich A, Simanov M, Porgador A, Rager-Zisman B, Orr N.

BMC Infect Dis. 2009 Feb 17;9:18. doi: 10.1186/1471-2334-9-18.

8.

Chemiluminescent optical fiber immunosensor for the detection of anti-West Nile virus IgG.

Herrmann S, Leshem B, Landes S, Rager-Zisman B, Marks RS.

Talanta. 2005 Mar 31;66(1):6-14. doi: 10.1016/j.talanta.2004.10.013. Epub 2004 Dec 18.

PMID:
18969954
9.

Two-dose measles immunization as a strategy to eliminate measles in the Middle East and Israel.

Belmaker I, Bazarsky E, Dukhan L, Shlomo C, Rager-Zisman B.

Isr Med Assoc J. 2008 Aug-Sep;10(8-9):640-5.

10.

The bioterrorism threat and dual-use biotechnological research: an Israeli perspective.

Friedman D, Rager-Zisman B, Bibi E, Keynan A.

Sci Eng Ethics. 2010 Mar;16(1):85-97. doi: 10.1007/s11948-008-9075-4. Epub 2008 Jun 19.

PMID:
18563629
11.

T7 phage display of Ep15 peptide for the detection of WNV IgG.

Herrmann S, Leshem B, Lobel L, Bin H, Mendelson E, Ben-Nathan D, Dussart P, Porgador A, Rager-Zisman B, Marks RS.

J Virol Methods. 2007 May;141(2):133-40. Epub 2007 Jan 9.

PMID:
17215048
12.

Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland.

Rouvio O, Dvorkin T, Amir-Kroll H, Atias D, Cohen IR, Rager-Zisman B, Porgador A.

Vaccine. 2005 May 20;23(27):3508-18.

PMID:
15855009
13.

Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Rager-Zisman B, Bazarsky E, Skibin A, Tam G, Chamney S, Belmaker I, Shai I, Kordysh E, Griffin DE.

Clin Diagn Lab Immunol. 2004 Sep;11(5):913-8.

14.

Viruses and autoimmune diseases--adapting Koch's postulates.

Denman AM, Rager-Zisman B.

Autoimmun Rev. 2004 Jul;3(5):355-61. Review.

PMID:
15288001
15.

Measles virus: evidence of an association with Hodgkin's disease.

Benharroch D, Shemer-Avni Y, Myint YY, Levy A, Mejirovsky E, Suprun I, Shendler Y, Prinsloo I, Ariad S, Rager-Zisman B, Sacks M, Gopas J.

Br J Cancer. 2004 Aug 2;91(3):572-9.

16.

Efficacy of prophylactic and therapeutic human immunoglobulin on West Nile virus infection.

Rager-Zisman B, Ben Nathan D.

Isr Med Assoc J. 2003 Oct;5(10):691. No abstract available.

17.

Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice.

Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B.

J Infect Dis. 2003 Jul 1;188(1):5-12. Epub 2003 Jun 23.

PMID:
12825165
18.

The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children.

Rager-Zisman B, Bazarsky E, Skibin A, Chamney S, Belmaker I, Shai I, Kordysh E, Griffin DE.

Vaccine. 2003 Jun 2;21(19-20):2580-8.

PMID:
12744894
19.

Medical research in Israel and the Israel biomedical database.

Berns DS, Rager-Zisman B.

Isr Med Assoc J. 2000 Nov;2(11):811-5.

20.

Development of a highly sensitive quantitative competitive PCR assay for the detection of murine cytomegalovirus DNA.

Palmon A, Tel-or S, Shai E, Rager-Zisman B, Burstein Y.

J Virol Methods. 2000 May;86(2):107-14.

PMID:
10785285
21.

Impact of virus infection on adults.

Rager-Zisman B.

Isr Med Assoc J. 2000 Mar;2(3):224. No abstract available.

22.

Antibodies to mycoplasma fermentans in HIV-positive heterosexual patients: seroprevalence and association with AIDS.

Horowitz S, Horowitz J, Hou L, Fuchs E, Rager-Zisman B, Jacobs E, Alkan M.

J Infect. 1998 Jan;36(1):79-84.

PMID:
9515674
23.

The effects of measles virus persistent infection on AP-1 transcription factor binding in neuroblastoma cells.

Fishman D, Wolfson M, Bazarski E, Segal S, Rager-Zisman B.

FEBS Lett. 1997 Jun 30;410(2-3):191-4.

24.

[Human herpesvirus-6: a new member of the herpesvirus family, a threat to AIDS, organ-transplanted and other immune deficient patients].

Kenigsberg S, Bantov J, Rager-Zisman B.

Harefuah. 1997 Mar 2;132(5):346-50. Review. Hebrew. No abstract available.

PMID:
9153879
25.

Persistent measles virus infection of murine neuroblastoma cells differentially affects the expression of PKC individual isoenzymes.

Bazarsky E, Wolfson M, Galron D, Granot Y, Argov S, Isakov N, Rager-Zisman B.

Virus Genes. 1997;15(3):227-34.

PMID:
9482588
26.

Treatment of murine cytomegalovirus salivary-gland infection by combined therapy with ganciclovir and thymic humoral factor gamma 2.

Palmon A, Blagerman S, Tel-Or S, Pecht M, Trainin N, Burstein Y, Rager-Zisman B.

Antiviral Res. 1996 Dec;33(1):55-64.

PMID:
8955853
27.

[Vaccination against measles--are we victims of our success?].

Rager-Zisman B.

Harefuah. 1996 Feb 15;130(4):248-9. Hebrew. No abstract available.

PMID:
8675118
28.

Tyrosine phosphorylation of measles virus P-phosphoprotein in persistently infected neuroblastoma cells.

Ofir R, Weinstein Y, Bazarsky E, Blagerman S, Wolfson M, Hunter T, Rager-Zisman B.

Virus Genes. 1996;13(3):203-10.

PMID:
9035364
29.

Tyrosine phosphorylation of measles virus nucleocapsid protein in persistently infected neuroblastoma cells.

Segev Y, Ofir R, Salzberg S, Heller A, Weinstein Y, Isakov N, Udem S, Wolfson M, Rager-Zisman B.

J Virol. 1995 Apr;69(4):2480-5.

30.

Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101.

Sredni B, Rosenthal-Galili Z, Michlin H, Sobelman D, Seger Y, Blagerman S, Kalechman Y, Rager-Zisman B.

Immunol Lett. 1994 Dec;43(3):159-65.

PMID:
7721328
31.

Reversal of the measles virus-mediated increase of phosphorylating activity in persistently infected mouse neuroblastoma cells by anti-measles virus antibodies.

Segev Y, Rager-Zisman B, Isakov N, Schneider-Schaulies S, ter Meulen V, Udem S, Segal S, Wolfson M.

J Gen Virol. 1994 Apr;75 ( Pt 4):819-27.

PMID:
8151298
32.

The effect of H-ras expression on tumorigenicity and immunogenicity of Balb/c 3T3 fibroblasts.

Ehrlich T, Wishniak O, Isakov N, Cohen O, Segal S, Rager-Zisman B, Gopas J.

Immunol Lett. 1993 Dec;39(1):3-8.

PMID:
8144187
33.

Thymic humoral factor, THF-gamma 2, enhances immunotherapy of murine cytomegalovirus (MCMV) infection by both CD4+ and CD8+ immune T cells.

Rager-Zisman B, Segev Y, Blagerman S, Palmon A, Tel-Or S, Pecht M, Trainin N, Burstein Y.

Immunol Lett. 1993 Dec;39(1):23-31.

PMID:
7908278
34.

The H-ras oncogene regulates expression of 70- and 45-kDa cell-surface molecules whose expression correlates with tumor-cell immunogenicity.

Gopas J, Ehrlich T, Cohen O, Wishniak O, Tainsky MA, Segal S, Rager-Zisman B, Isakov N.

Int J Cancer. 1992 Sep 9;52(2):329-35.

PMID:
1521919
35.

Antibody-dependent transcriptional regulation of measles virus in persistently infected neural cells.

Schneider-Schaulies S, Liebert UG, Segev Y, Rager-Zisman B, Wolfson M, ter Meulen V.

J Virol. 1992 Sep;66(9):5534-41.

36.

Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells.

Gopas J, Itzhaky D, Segev Y, Salzberg S, Trink B, Isakov N, Rager-Zisman B.

Cancer Immunol Immunother. 1992;34(5):313-20.

PMID:
1347254
37.

Differential expression of the H-2Dk MHC class-I antigen and tissue inhibitor of metalloproteinases in metastatic and nonmetastatic T-10 fibrosarcoma cells.

Har-Vardi I, Gopas J, Rager-Zisman B, Hammerling GJ, Segal S, Aboud M.

Invasion Metastasis. 1992;12(5-6):301-8.

PMID:
1298741
38.

Resistance to NK and metastatic potential of fibrosarcoma cells is associated with products encoded by the H-2D region.

Rager-Zisman B, Aboud M, Gopas J, Har-Vardi I, Hämmerling GJ, Segal S.

Semin Cancer Biol. 1991 Oct;2(5):329-36. Review.

PMID:
1773048
39.

Regulatory effects of persistent measles virus infection on tumorigenicity and protooncogene expression in neuroblastoma cells.

Wolfson M, Gopas J, Katorza A, Udem SA, Segal S, Rager-Zisman B.

Cancer Detect Prev. 1991;15(3):171-6.

PMID:
2059960
40.

[Live poliovaccines--immunological aspects].

Rager-Zisman B, Schattner A.

Harefuah. 1990 Apr 1;118(7):417-9. Hebrew. No abstract available.

PMID:
2351349
41.

Natural killer (NK) cell response after vaccination of volunteers with killed influenza vaccine.

Schapiro JM, Segev Y, Rannon L, Alkan M, Rager-Zisman B.

J Med Virol. 1990 Mar;30(3):196-200.

PMID:
2341835
42.

Virus-induced autoimmunity.

Schattner A, Rager-Zisman B.

Rev Infect Dis. 1990 Mar-Apr;12(2):204-22. Review.

PMID:
2091619
43.

Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-gamma 2) treated immune spleen cells.

Rager-Zisman B, Zuckerman F, Benharroch D, Pecht M, Burstein Y, Trainin N.

Clin Exp Immunol. 1990 Feb;79(2):246-52.

44.

NK sensitivity, H-2 expression and metastatic potential: analysis of H-2Dk gene transfected fibrosarcoma cells.

Gopas J, Rager-Zisman B, Har-Vardi I, Hammerling GJ, Bar-Eli M, Segal S.

J Immunogenet. 1989 Aug-Oct;16(4-5):305-13.

PMID:
2639905
45.
46.

The relationship between MHC antigen expression and metastasis.

Gopas J, Rager-Zisman B, Bar-Eli M, Hämmerling GJ, Segal S.

Adv Cancer Res. 1989;53:89-115. Review.

PMID:
2678949
47.

Virus-induced autoimmunity.

Rager-Zisman B.

Isr J Med Sci. 1988 Jul;24(7):363-5.

PMID:
3261285
49.

Influence of H-2K transfection on susceptibility of fibrosarcoma tumor cells to natural killer (NK) cells.

Gopas J, Segal S, Hammerling G, Bar-Eli M, Rager-Zisman B.

Immunol Lett. 1988 Mar;17(3):261-5.

PMID:
2836303
50.

NK sensitivity, H-2, c-K-ras proto-oncogene expression and metastases: analysis of the metastatic potential of H-2 gene transfected fibrosarcoma cells.

Rager-Zisman B, Gopas J, Bar-Eli M, Har-Vardi I, Hammerling GJ, Segal S.

Adv Exp Med Biol. 1988;233:151-60.

PMID:
3066149

Supplemental Content

Loading ...
Support Center